These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 1778325)

  • 41. Adverse reactions and serologic response to a booster dose of acellular pertussis vaccine in children immunized with acellular or whole-cell vaccine as infants.
    Blennow M; Granström M
    Pediatrics; 1989 Jul; 84(1):62-7. PubMed ID: 2544850
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Monitoring of a whooping cough epidemic 1994/95 in Switzerland using the sentinel notification system. Sentinella Registry].
    Matter HC; Schmidt-Schläpfer G; Zimmermann H
    Schweiz Med Wochenschr; 1996 Aug; 126(34):1423-32. PubMed ID: 8848704
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The burden of Haemophilus influenzae type b disease in Australia and an economic appraisal of the vaccine PRP-OMP.
    Harris A; Hendrie D; Bower C; Payne J; de Klerk N; Stanley F
    Med J Aust; 1994 Apr; 160(8):483-8. PubMed ID: 8170423
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical efficacy of the Japanese acellular pertussis vaccine after intrafamiliar exposure to pertussis patients.
    Isomura S; Suzuki S; Sato Y
    Dev Biol Stand; 1985; 61():531-7. PubMed ID: 3914964
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Age at pertussis immunization as it relates to current epidemiology and disease control.
    Funkhouser AW; Wassilak SG; Hinman AR; Orenstein WA; Mortimer EA
    Tokai J Exp Clin Med; 1988; 13 Suppl():111-5. PubMed ID: 3273610
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Epidemiology of bacterial meningitis in France in 1999].
    Perrocheau A; De Benoist AC; Six C; Goulet V; Decludt B; Levy-Bruhl D
    Ann Med Interne (Paris); 2002 Sep; 153(5):311-7. PubMed ID: 12442076
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants.
    Dashefsky B; Wald E; Guerra N; Byers C
    Pediatrics; 1990 Apr; 85(4 Pt 2):682-9. PubMed ID: 2107519
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Disease burden and case management of bacterial meningitis among children under 5 years of age in Saudi Arabia.
    Al-Mazrou YY; Musa EK; Abdalla MN; Al-Jeffri MH; Al-Hajjar SH; Mohamed OM
    Saudi Med J; 2003 Dec; 24(12):1300-7. PubMed ID: 14710273
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Acute encephalitis and bacterial meningitis in children in Aichi Prefecture (1984-1993)].
    Kuriki M; Fujihra N; Hasegawa S; Fujioka M
    Nihon Koshu Eisei Zasshi; 1995 May; 42(5):338-45. PubMed ID: 7647351
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Incidence of bacterial meningitis (2001-2005) in Lazio, Italy: the results of a integrated surveillance system.
    Giorgi Rossi P; Mantovani J; Ferroni E; Forcina A; Stanghellini E; Curtale F; Borgia P
    BMC Infect Dis; 2009 Feb; 9():13. PubMed ID: 19196453
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Acellular pertussis vaccines and fatal infections.
    Kimura M; Kuno-Sakai H
    Lancet; 1988 Apr; 1(8590):881-2. PubMed ID: 2895385
    [No Abstract]   [Full Text] [Related]  

  • 52. [Purulent meningitis. New findings on pathogenesis].
    Giacchino R; Giambartolomei G
    Minerva Pediatr; 1992 Oct; 44(10 Suppl 1):21-6. PubMed ID: 1470072
    [No Abstract]   [Full Text] [Related]  

  • 53. Meningitis B vaccine will not be extended to all under-11s.
    Nurs Stand; 2016 May; 30(36):11. PubMed ID: 27154088
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Scientists Receive Award for Meningitis Vaccine Research.
    Voelker R
    JAMA; 2017 Feb; 317(7):688. PubMed ID: 28241340
    [No Abstract]   [Full Text] [Related]  

  • 55. Calculation of efficacy of acellular pertussis vaccine from the number of pertussis patients and vaccinees in three areas.
    Ohkuni H; Yabiku M; Togawa M; Fukai K; Yosida I; Minekawa Y; Kitamura T
    Dev Biol Stand; 1991; 73():43-9. PubMed ID: 1778332
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of acellular pertussis vaccine in Japan--comparison of two areas, one area where immunization started at 6 months and the other area at over 2 years of age--Regional Surveillance Committee on Tuberculosis and Infectious Diseases of Osaka.
    Ohkuni H; Kitaura T; Tamai T; Takasugi Y; Sugimoto T; Fukai K
    Tokai J Exp Clin Med; 1988; 13 Suppl():51-4. PubMed ID: 3273619
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age.
    Gustafsson L; Hessel L; Storsaeter J; Olin P
    Pediatrics; 2006 Sep; 118(3):978-84. PubMed ID: 16950988
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epidemiology of bacterial meningitis in Niamey, Niger, 1981-96.
    Campagne G; Schuchat A; Djibo S; Ousséini A; Cissé L; Chippaux JP
    Bull World Health Organ; 1999; 77(6):499-508. PubMed ID: 10427935
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Relationship between bacterial meningitis and acellular pertussis vaccine.
    Yabiku M; Ohkuni H; Shiomi M; Ishii T; Shimotuji T
    Dev Biol Stand; 1991; 73():315-21. PubMed ID: 1778325
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.